clinical trial · NCT07497386
A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.·phase2·not yet recruiting·n = 150
Unresectable Locally Recurrent Breast CancerUnresectable Locally Metastatic Breast CancerTrastuzumab Rezetecan for InjectionTrastuzumab Deruxtecan for Injection
brief summary
The study is designed to compare the efficacy and safety of different dose groups of Trastuzumab Rezetecan or Trastuzumab Deruxtecan in patients with HR-positive, HER2-low unresectable locally recurrent/metastatic breast cancer. It will also exploratively evaluate the pharmacokinetic profile and immunogenicity of Trastuzumab Rezetecan.
started
Apr 1, 2026
primary completion
Jun 1, 2028
completion
Dec 1, 2028
last updated
Mar 27, 2026
official title
A Randomized, Open-Label, Multicenter Phase II Clinical Study of Different Doses of Trastuzumab Rezetecan for Injection or Trastuzumab Deruxtecan for Injection in the Treatment of Unresectable Locally Recurrent/Metastatic Breast Cancer With HR-Positive and HER2-Low Expression
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol